597 related articles for article (PubMed ID: 19402821)
41. Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1).
Pearce LR; Alton GR; Richter DT; Kath JC; Lingardo L; Chapman J; Hwang C; Alessi DR
Biochem J; 2010 Oct; 431(2):245-55. PubMed ID: 20704563
[TBL] [Abstract][Full Text] [Related]
42. A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation.
Yang G; Murashige DS; Humphrey SJ; James DE
Cell Rep; 2015 Aug; 12(6):937-43. PubMed ID: 26235620
[TBL] [Abstract][Full Text] [Related]
43. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
[TBL] [Abstract][Full Text] [Related]
44. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
[TBL] [Abstract][Full Text] [Related]
45. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis.
Spangle JM; Münger K
J Virol; 2010 Sep; 84(18):9398-407. PubMed ID: 20631133
[TBL] [Abstract][Full Text] [Related]
46. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2.
Li W; Petrimpol M; Molle KD; Hall MN; Battegay EJ; Humar R
Circ Res; 2007 Jan; 100(1):79-87. PubMed ID: 17110594
[TBL] [Abstract][Full Text] [Related]
47. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
48. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
[TBL] [Abstract][Full Text] [Related]
49. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
[TBL] [Abstract][Full Text] [Related]
50. The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection.
Clippinger AJ; Maguire TG; Alwine JC
J Virol; 2011 Apr; 85(8):3930-9. PubMed ID: 21307192
[TBL] [Abstract][Full Text] [Related]
51. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.
Chresta CM; Davies BR; Hickson I; Harding T; Cosulich S; Critchlow SE; Vincent JP; Ellston R; Jones D; Sini P; James D; Howard Z; Dudley P; Hughes G; Smith L; Maguire S; Hummersone M; Malagu K; Menear K; Jenkins R; Jacobsen M; Smith GC; Guichard S; Pass M
Cancer Res; 2010 Jan; 70(1):288-98. PubMed ID: 20028854
[TBL] [Abstract][Full Text] [Related]
52. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis.
Thedieck K; Polak P; Kim ML; Molle KD; Cohen A; Jenö P; Arrieumerlou C; Hall MN
PLoS One; 2007 Nov; 2(11):e1217. PubMed ID: 18030348
[TBL] [Abstract][Full Text] [Related]
53. The ATM inhibitor KU-55933 suppresses cell proliferation and induces apoptosis by blocking Akt in cancer cells with overactivated Akt.
Li Y; Yang DQ
Mol Cancer Ther; 2010 Jan; 9(1):113-25. PubMed ID: 20053781
[TBL] [Abstract][Full Text] [Related]
54. Epimagnolin targeting on an active pocket of mammalian target of rapamycin suppressed cell transformation and colony growth of lung cancer cells.
Yoo SM; Lee CJ; Kang HC; Lee HS; Lee JY; Kim KD; Kim DJ; An HJ; Cho YY
Mol Carcinog; 2019 Jul; 58(7):1221-1233. PubMed ID: 30887599
[TBL] [Abstract][Full Text] [Related]
55. Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes.
Pham PT; Heydrick SJ; Fox HL; Kimball SR; Jefferson LS; Lynch CJ
J Cell Biochem; 2000 Sep; 79(3):427-41. PubMed ID: 10972980
[TBL] [Abstract][Full Text] [Related]
56. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
57. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
58. Intestinal cell kinase, a MAP kinase-related kinase, regulates proliferation and G1 cell cycle progression of intestinal epithelial cells.
Fu Z; Kim J; Vidrich A; Sturgill TW; Cohn SM
Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G632-40. PubMed ID: 19696144
[TBL] [Abstract][Full Text] [Related]
59. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
60. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
